Welcome to our dedicated page for Ipsen Sa news (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on Ipsen Sa stock.
Ipsen SA (ADR: IPSEY) generates a steady flow of news centered on its activities as a global, mid-sized biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. This news page aggregates company announcements, partner releases and regulatory updates that mention Ipsen and its ADR program, giving readers a focused view of developments that can influence perceptions of IPSEY.
Recent news highlights Ipsen’s role in advancing specialty care medicines. In oncology, the company has reported Phase III NAPOLI 3 trial results for an investigational Onivyde-based regimen (NALIRIFOX) in previously untreated metastatic pancreatic ductal adenocarcinoma, with statistically significant improvements in overall and progression-free survival compared to a nab-paclitaxel plus gemcitabine regimen. Ipsen has also nominated a first clinical drug candidate from its multi-year oncology collaboration with Marengo Therapeutics, based on Marengo’s STAR T cell activator platform for solid tumors.
In rare diseases, news items cover Ipsen’s work in pediatric cholestatic liver diseases and ultra-rare conditions. Examples include Health Canada’s approval of Bylvay (odevixibat) for pruritus due to Progressive Familial Intrahepatic Cholestasis, under a partnership with Medison Pharma, and regulatory interactions for palovarotene in fibrodysplasia ossificans progressiva, including a CHMP negative opinion and a U.S. FDA Complete Response Letter. Corporate news also details Ipsen’s agreement to acquire Albireo, adding Bylvay and other bile acid modulators to its rare disease portfolio.
Neuroscience and rare neurological disease updates feature Ipsen’s collaboration with Skyhawk Therapeutics to discover RNA-targeting small molecules for rare neurological diseases. Partner announcements describe Ipsen’s option to obtain exclusive global rights to development candidates and its responsibility for later-stage development and commercialization.
Investors and observers can use this news feed to follow Ipsen’s clinical trial readouts, regulatory decisions, licensing deals, acquisitions and capital markets disclosures that reference IPSEY. Regularly reviewing these updates can help contextualize the company’s therapeutic focus and strategic direction as reflected in public announcements.
Ipsen has reported essential updates regarding its share capital as of 30 June 2022. The total number of shares amount to 83,814,526, with a gross total of 132,114,538 voting rights and a net total of 130,987,438 voting rights. This information follows the regulations outlined by the French Commercial Code and the Autorité des Marchés Financiers. The gross total includes shares with double voting rights and treasury shares, while the net total excludes shares without voting rights.
IPSEN SA has reported updates related to its liquidity agreement with NATIXIS ODDO BHF as of June 30, 2022. The dedicated liquidity account includes 27,006 shares and €2,035,791.62. Previously, 12,751 shares and €3,137,934.80 were allocated. From January 1 to June 30, 2022, there were 1,568 purchase and 1,233 sell transactions, with volumes of 185,471 shares (€17.7M) purchased and 192,518 shares (€18.3M) sold. IPSEN, a biopharmaceutical company, generated €2.6 billion in Specialty Care sales in FY 2021 and operates globally.
IPSEN announced details of share transactions aggregating significant trading data. On June 27, 2022, the company acquired 6,950 shares at a weighted average price of €85.0020, with additional transactions on June 29 totaling 776 shares at an average price of €85.3929. The total volume of shares acquired across these days reached 7,726 at an average price of €85.0413. These transactions were executed on the XPAR and CEUX platforms, indicating ongoing strategic movements in shareholding.
Ipsen announced that the FDA has accepted for Priority Review its resubmitted NDA for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (FOP). This acceptance signifies a critical step for patients with FOP, as there are currently no approved treatments. The Prescription Drug User Fee Act goal date is set for December 29, 2022. Palovarotene has already been approved in Canada and is undergoing review in the EU. Ipsen emphasizes its commitment to developing innovative treatments for rare diseases despite regulatory challenges.
IPSEN reported significant trading activity with a total of 8,762 shares exchanged between June 20 and June 23, 2022. The daily weighted average price ranged from 82.7186 to 84.1235, with an overall average of 83.1677. This trading data was sourced from the XPAR platform. The report details individual transactions, emphasizing the total volume and average pricing during the specified period, which is critical for investors monitoring stock performance.
Ipsen announced the acquisition of Epizyme for an all-cash tender offer at $1.45 per share, plus a contingent value right of $1.00 per share. The deal, unanimously approved by both boards, aims to enhance Ipsen's oncology portfolio by focusing on Tazverik®, an EZH2 inhibitor approved for treating specific types of lymphoma. Ipsen anticipates that the acquisition will strengthen its market presence in oncology, despite expected moderate dilution in core operating income until the end of 2024.
Ipsen announced a definitive merger agreement to acquire Epizyme, focusing on Tazverik® (tazemetostat), an EZH2a inhibitor approved in the U.S. The acquisition involves an all-cash tender offer of $1.45 per share and a contingent value right (CVR) of $1.00 per share. Anticipating closure by Q3 2022, this deal enhances Ipsen’s oncology portfolio, aiming for increased sales and leveraging existing infrastructure. The transaction is expected to be moderately dilutive to Ipsen’s core operating income until 2024. Royalty Pharma, holding 20.5% of Epizyme shares, supports the acquisition.
IPSEN has reported its aggregated share acquisition data for the week of June 13-17, 2022. During this period, the company acquired a total of 27,390 shares at a daily weighted average price of €83.6876. The highest daily acquisitions occurred on June 13 with 7,500 shares at an average price of €86.2925, while the lowest was on June 15 with 2,500 shares priced at €84.1820. This information is crucial for investors monitoring IPSEN's share buyback activities.
IPSEN has released a regulatory update detailing the aggregated share transactions conducted on the XPAR platform. On June 6, 2022, a total of 3,500 shares were acquired at a daily weighted average price of €93.7123. Cumulatively, 18,500 shares have been transacted at an average price of €91.8285. The report underlines the company's active share management and compliance with market regulations, emphasizing transparency in financial operations.
Ipsen has reported the total number of shares composing its share capital as of May 31, 2022, which stands at 83,814,526 shares. The gross total of voting rights is 132,125,928, while the net total is 131,073,533. This report aligns with the French Commercial Code regulations.
The net total excludes shares without voting rights, ensuring compliance with statutory obligations concerning threshold crossing declarations.